GAL and neoplasm: Thus, peptide-based, antibody-based, and small molecule-based Gal-1 inhibitors can transiently normalize tumor vasculature to increase the sensitivity of tumors to chemo- and immunotherapy and have the potential to significantly enhance clinical success.